Insight Molecular Diagnostics (IMDX) Common Equity (2015 - 2026)

Insight Molecular Diagnostics has reported Common Equity for 12 years, with the latest figure at -$10.7 million in Q1 2026.

• Quarterly Common Equity fell 204.63% year-over-year to -$10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.7 million (down 204.63% YoY) and the FY2025 annual result came in at -$31.5 million, down 156.35% from the prior year.
• Common Equity advanced to -$10.7 million in Q1 2026 per IMDX's latest filing, from -$31.5 million in the prior quarter.
• Over five years, Common Equity peaked at $83.2 million in Q2 2022 and troughed at -$31.5 million in Q4 2025.
• A 5-year average of $22.4 million and a median of $20.5 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2025 and 2026: Common Equity declined 11.82% in 2025, then sank 204.63% in 2026.
• Over 5 years, Common Equity stood at $34.3 million in 2022, then tumbled by 40.31% to $20.5 million in 2023, then sank by 159.97% to -$12.3 million in 2024, then slumped by 156.35% to -$31.5 million in 2025, then surged by 66.02% to -$10.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$10.7 million, -$31.5 million, and -$9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.